Statement Of Cash Flows [Abstract]

Xbrane Biopharma - Filing #689990

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
172 513 SEK
172 513 SEK
188 376 SEK
188 376 SEK
Adjustments to reconcile profit (loss) [abstract]
Adjustments for decrease (increase) in inventories
50 260 SEK
SEK
Adjustments for decrease (increase) in trade accounts receivable
1 699 SEK
61 086 SEK
Other adjustments for non-cash items
9 327 SEK
7 180 SEK
Income taxes paid (refund), classified as operating activities
SEK
SEK
Cash flows from (used in) operating activities
193 918 SEK
219 610 SEK
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
11 616 SEK
27 678 SEK
Purchase of intangible assets, classified as investing activities
48 509 SEK
49 672 SEK
Cash flows from (used in) investing activities
60 125 SEK
77 350 SEK
Cash flows from (used in) financing activities [abstract]
Proceeds from changes in ownership interests in subsidiaries that do not result in loss of control
551,000 SEK
SEK
Proceeds from issuing shares
170 000 SEK
380 870 SEK
Repayments of borrowings, classified as financing activities
SEK
SEK
Payments of lease liabilities, classified as financing activities
8 337 SEK
7 273 SEK
Cash flows from (used in) financing activities
148 864 SEK
349 365 SEK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
105 179 SEK
52 406 SEK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
4 046 SEK
1 393 SEK
Cash and cash equivalents
193 994 SEK
295 180 SEK
243 139 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.